Ronald Scott

Adesh Kaul will join Basilea Pharmaceutica’s Management Committee as Chief Corporate Development Officer

BASEL, 05-Mar-2018 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Adesh Kaul will join Basilea's Management Committee as…

6 years ago

U.S. FDA designated Basilea Pharmaceutica’s isavuconazole as Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis

Basel, Switzerland, 11-12-2013 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated…

10 years ago

Basilea Pharmaceutica Ltd awarded USD 89M contract by U.S. Department of Health and Human Services division BARDA for the development of its novel antibiotic BAL30072

BAL30072 current multiple ascending dose study reached maximum tolerated dose Further development, including combination studies with carbapenems, planned under BARDA…

11 years ago